These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 18248522)

  • 1. Can the risk of gadolinium be extrapolated to lanthanum?
    De Broe ME
    Semin Dial; 2008; 21(2):142-4. PubMed ID: 18248522
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patient characteristics and risk factors for nephrogenic systemic fibrosis following gadolinium exposure.
    Grobner T; Prischl FC
    Semin Dial; 2008; 21(2):135-9. PubMed ID: 18226001
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nephrogenic systemic fibrosis risk: is there a difference between gadolinium-based contrast agents?
    Penfield JG; Reilly RF
    Semin Dial; 2008; 21(2):129-34. PubMed ID: 18225999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tissue distribution and kinetics of gadolinium and nephrogenic systemic fibrosis.
    Abraham JL; Thakral C
    Eur J Radiol; 2008 May; 66(2):200-7. PubMed ID: 18374532
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tissue deposition of gadolinium and development of NSF: a convergence of factors.
    Perazella MA
    Semin Dial; 2008; 21(2):150-4. PubMed ID: 18226004
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dialytic therapies to prevent NSF following gadolinium exposure in high-risk patients.
    Rodby RA
    Semin Dial; 2008; 21(2):145-9. PubMed ID: 18226002
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nephrogenic systemic fibrosis and gadolinium-based contrast: medico-legal implications.
    Houck CM; Pristave RJ; Kannensohn KJ
    Semin Dial; 2008; 21(2):166-70. PubMed ID: 18226003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nephrogenic systemic fibrosis: a population study examining the relationship of disease development to gadolinium exposure.
    Deo A; Fogel M; Cowper SE
    Clin J Am Soc Nephrol; 2007 Mar; 2(2):264-7. PubMed ID: 17699423
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nephrogenic systemic fibrosis--implications for nephrologists.
    Saab G; Abu-Alfa A
    Eur J Radiol; 2008 May; 66(2):208-12. PubMed ID: 18342470
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MRI gadolinium-based contrast agents. Radiologists beware!
    Goullé JP; Cattanéo A; Saussereau E; Mahieu L; Guerbet M; Lacroix C
    Ann Pharm Fr; 2009 Sep; 67(5):335-9. PubMed ID: 19695369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nephrogenic systemic fibrosis associated with gadolinium based contrast agents: a summary of the medical literature reporting.
    Broome DR
    Eur J Radiol; 2008 May; 66(2):230-4. PubMed ID: 18372138
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Nephrogenic systemic fibrosis].
    Cavallini L; Abaterusso C; Bedogna V; Pertica N; Loschiavo C; Lupo A
    G Ital Nefrol; 2008; 25(1):14-20. PubMed ID: 18264914
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gadolinium-associated nephrogenic systemic fibrosis: the need for nephrologists' awareness.
    Canavese C; Mereu MC; Aime S; Lazzarich E; Fenoglio R; Quaglia M; Stratta P
    J Nephrol; 2008; 21(3):324-36. PubMed ID: 18587720
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nephrogenic systemic fibrosis: more questions and some answers.
    Morcos SK; Thomsen HS
    Nephron Clin Pract; 2008; 110(1):c24-31; discussion c32. PubMed ID: 18688172
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nephrogenic systemic fibrosis and gadolinium-based contrast: what's a nephrologist to do?
    Perazella MA
    Semin Dial; 2008; 21(2):121-2. PubMed ID: 18248521
    [No Abstract]   [Full Text] [Related]  

  • 16. Nephrogenic systemic fibrosis an unsolved riddle.
    Graziani G; Montanelli A; Brambilla S; Balzarini L
    J Nephrol; 2009; 22(2):203-7. PubMed ID: 19384837
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Strong association between the use of gadolinium-based contrast agents with nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis.
    Jamboti J
    Intern Med J; 2007 Jul; 37(7):508-9; author reply 509. PubMed ID: 17547734
    [No Abstract]   [Full Text] [Related]  

  • 18. Extracellular gadolinium-based contrast media: an overview.
    Bellin MF; Van Der Molen AJ
    Eur J Radiol; 2008 May; 66(2):160-7. PubMed ID: 18358659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nephrogenic systemic fibrosis: a gadolinium-associated fibrosing disorder in patients with renal dysfunction.
    Kay J
    Ann Rheum Dis; 2008 Dec; 67 Suppl 3():iii66-9. PubMed ID: 19022818
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toxicity of contrast media: an update.
    ten Dam MA; Wetzels JF
    Neth J Med; 2008 Nov; 66(10):416-22. PubMed ID: 19011267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.